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Abstract
Purpose—To develop polymer nanoassemblies (PNAs) modified with halofluorochromic dyes to 
allow for the detection of liver metastatic colorectal cancer (CRC) to improve therapeutic 
outcomes.
Methods—We combine experimental and computational approaches to evaluate macroscopic and 
microscopic PNA distributions in patient-derived xenograft primary and orthotropic liver 
metastatic CRC tumors. Halofluorochromic and non-halofluorochromic PNAs (hfPNAs and n-
hfPNAs) were prepared from poly(ethylene glycol), fluorescent dyes (Nile blue, Alexa546, and 
IR820), and hydrophobic groups (palmitate), all of which were covalently tethered to a cationic 
polymer scaffold [poly(ethylene imine) or poly(lysine)] forming particles with an average 
diameter < 30 nm.
Results—Dye-conjugated PNAs showed no aggregation under opsonizing conditions for 24 h 
and displayed low tissue diffusion and cellular uptake. Both hfPNAs and n-hfPNAs accumulated 
in primary and liver metastatic CRC tumors within 12 h post intravenous injection. In comparison 
to n-hfPNAs, hfPNAs fluoresced strongly only in the acidic tumor microenvironment (pH<7.0) 
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and distinguished small metastatic CRC tumors from healthy liver stroma. Computational 
simulations revealed that PNAs would steadily accumulate mainly in acidic (hypoxic) interstitium 
of metastatic tumors, independently of the vascularization degree of the tissue surrounding the 
lesions.
Conclusion—The combined experimental and computational data confirms that hfPNAs 
detecting acidic tumor tissue can be used to identify small liver metastatic CRC tumors with 
improved accuracy.
Keywords
Theranostics; tumor microenvironment; tissue acidity; computational tumor simulation; 
nanoparticle distribution simulation
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of deaths in adult cancer patients in the 
United States, and its metastasis accounts for more than 90% of the mortality (1, 2). 
However, successful treatment of CRC is often hampered by the lack of methods to detect 
metastatic CRC tumors early and accurately deliver anticancer drugs to the tumor tissue with 
low side effects. Nanoparticles are promising tools to address these problems because they 
can selectively accumulate in solid tumors and thus may deliver therapeutic and imaging 
agents in higher concentrations to metastatic CRC. Although many nanoparticles have been 
developed to integrate therapy and diagnosis of cancer, their clinical benefits remain elusive 
due to several factors affecting in vivo performance of ‘theranostic’ nanoparticles.
One major factor is the tissue microenvironment that changes during treatment or imaging of 
metastatic CRC tumors. In comparison to primary CRC tumors comprising large lesions and 
high blood vessel density, metastatic CRC tumors are generally too small to develop blood 
vessels inducing enhanced nanoparticle accumulation in the tumor tissue. In addition, CRC 
metastasizes mainly to the liver, which has a unique tissue structure including macrophages 
and stromal cells in direct contact with metastatic tumor foci (3). Therefore, nanoparticles 
have difficulty to deliver therapeutic and imaging agents selectively to liver metastatic CRC 
tumor lesions without being taken up by Kupffer cells or hepatocytes.
Imaging dyes are another factor affecting diagnostic performance of theranostic 
nanoparticles. Although magnetic resonance imaging (MRI), positron emission tomography 
(PET), computerized tomography (CT), and other advanced imaging techniques are 
available, intraoperative imaging using fluorescent dyes is the most cost-effective and direct 
way to visualize tumors and cancer cells (4, 5). During intraoperative fluorescence imaging, 
clinicians visualize fluorescent dyes accumulating in solid tumors and determine the 
accurate size and shape of the tumor for resection from the healthy organ. Intraoperative 
fluorescence imaging can overcome some clinical limitations of fluorescence imaging such 
as limited tissue penetration. MRI and CT generally monitor contrast agents moving through 
healthy organs and identify structural abnormalities caused by tumor tissue, but these 
indirect imaging techniques often show imaging artifacts and fail to detect small metastatic 
tumors inducing little or no changes to tissue structure (6). Fluorescence imaging detects 
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fluorescent dyes accumulating in tumor cells, and the direct imaging of cells can provide 
better imaging resolution than MRI or CT. However, fluorescent dyes have limited 
selectivity in distinguishing tumor from normal cells, and thus have poor diagnostic 
properties such as low signal-to-noise ratios, high background signals, short half-lives in 
tumor tissue, and rapid clearance from the blood (7, 8).
The third most common factor is physicochemical properties of theranostic nanoparticles, 
such as size, surface charge, and stability. Particles with an average diameter of 30 nm are 
known to accumulate in solid tumors most efficiently (9–11). Particles with an anionic 
surface can prevent protein adsorption in the body and prolong blood circulation time, but 
anionic particles avoiding opsonization do not necessarily improve tumor accumulation in 
comparison to particles with a neutral surface (12–14). Particle stability is most important to 
ensure preferential accumulation of nanoparticles in tumors (15–17). However, these 
properties change unpredictably during nanoparticle production, storage, and use (18–20).
To understand the complex interplay among these factors, we have developed polymer 
nanoassemblies (PNAs) with uniform particle size, enhanced physical and chemical stability, 
and functional versatility (21–25). PNAs are made from biocompatible polymers and small 
molecule components such as poly(ethylene glycol) (PEG), poly(ethylene imine) (PEI), 
poly(lysine) (PLL), and palmitic acid (PAL), which are tethered each other through a 
coupling reaction between a scaffold (PEI or PLL) and grafts (PEG and PAL). In previous 
studies, we confirmed that PNAs are uniform in shape and size with an average diameter of 
30 nm, and they can fine-tune the entrapment and release of various model anticancer drugs 
in comparison to other FDA-approved injection formulations such as polymer micelles and 
modified cyclodextrin (26–29). PNAs were physically and chemically stable to prevent 
changes in particle diameter, surface charge, and shape while entrapping various therapeutic 
and imaging molecules concurrently in the core (21, 22, 27, 30–34).
We recently verified that PNAs entrapping imaging dyes that change fluorescence as a 
function of solvent pH (halofluorochromism) would be particularly useful to elucidate how 
nanoparticles distribute in tumors with acidic tissue environments(28, 35). Tumor tissue is 
acidic as rapidly proliferating cancer cells produce a large amount of lactic acid during 
proliferation. This phenomenon, also known as the Warburg effect (36, 37), is responsible 
for various changes in the accumulation, stability, and pharmacology of drugs in tumors. The 
acidic tumor tissue can be used to trigger drug release from nanoparticle carriers or 
differentiate tumor from normal tissue by using halofluorochromic dyes such as Nile blue 
(NB). Our previous observations revealed that NB quenches its fluorescence in water but 
remains fluorescent in the core of PNAs while the dye-loaded PNAs change fluorescence 
wavelength and intensity in response to environmental pH (26–28). We hypothesize that NB-
loaded PNAs may detect subtle changes in tissue pH and thus allow for early and accurate 
detection of small liver metastatic CRC tumors for intraoperative imaging.
To test this hypothesis, this study focuses on experimental determination and computational 
simulation of PNA distribution in liver metastatic CRC tumors (Figure 1). PNAs entrapping 
fluorescent dyes are used to trace the accumulation, distribution, and clearance of 
nanoparticles in mice bearing patient-derived xenograft (PDX) or orthotopic liver metastatic 
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CRC tumors. hfPNA accumulation in metastatic CRC tumors is analyzed via computational 
modeling simulating nanoparticle drug delivery. We previously confirmed that computer-
assisted simulations accurately predict the clinical impact of nanoparticle design on drug 
delivery related to various biological parameters such as tumor size, blood vessel density, 
and cellular responses to a specific drug (35, 38–40). Therefore, the goal of the current study 
is to confirm the feasibility of hfPNAs to detect metastatic CRC tumors in the liver and thus 
better elucidate biological conditions that can maximize hfPNA theranostic utility in future 
applications.
MATERIALS AND METHODS
Materials and cells
α-Succinimidyloxysuccinyl-ω-methoxy-PEG (5 kDa, NHS-activated PEG) was purchased 
from NOF America (White Plains, NY). Branched PEI (25 kDa), PLL (30–70 kDa, HBr 
salt), palmitoyl chloride, acetic anhydride, sucrose, HEPES sodium salt, agarose, NB, IR820 
and NHS ester-activated Alexa Fluor® 546 dye (Alexa546) were purchased from Sigma 
Aldrich (St. Louis, MO). DMSO, THF, pyridine, methanol, diethyl ether, nuclear staining 
dye Hoechst 33342, DAPI, Mitotracker Green (MG), dialysis membrane with 3.5 or 100 
kDa molecular weight cutoff (MWCO), chamber slides, preparative size exclusion columns 
(PD Minitrap, G-25, 3.5 mL), and phosphate buffer solutions (50 mM, pH 7.4, 7.0 and 6.0) 
were purchased from Fisher Scientific (Waltham, MA). Paraformaldehyde solution (4%) was 
purchased from Polysciences (Warrington, PA). Optimal cutting temperature compound 
(OCT) was purchased from Andwin Scientific (Schaumburg, IL). Mouse EpCAM antibodies 
were purchased from LSBio (Seattle, WA) and mouse CD31 and donkey anti-mouse IgG 
antibodies labelled with NL637 dyes were purchased from R&D Systems (Minneapolis, 
MN). An aqueous permanent mounting medium was purchased from Dako (Carpinteria, 
CA). McCoy’s 5A media, phosphate buffered saline (PBS) and 0.05% trypsin/EDTA were 
purchased from GE Healthcare (Logan, UT). The fetal bovine serum (FBS) was purchased 
from Atlanta Biologicals (Flowery Branch, GA). Human CRC cell lines (HT29 and 
HCT116) were purchased from the American Type Culture Collection (ATCC, Manassas, 
VA). CRC cells were cultured in a humidified environment with 5% CO2 at 37°C in 
McCoy’s 5A media supplemented with 10% FBS following the ATCC recommendations.
Animal models
Patient-derived xenograft (PDX) and orthotopic liver metastatic CRC tumor models were 
used in this study. NOD-SCID gamma mice between 6 to 8 weeks old were purchased from 
the Jackson Laboratory (Bar Harbor, ME) to develop PDX tumor models. All animal 
experiments were performed in accordance with the Institutional Animal Care and Use 
Committee (IACUC) and were approved by the Institutional Review Board (IRB) of the 
University of Kentucky. An original patient CRC tumor sample (F0) was implanted into 
mouse flanks to develop the first generation PDX tumor (F1). The F1 tumor (1 cm3) was 
resected, divided into small pieces (2 mm3), and implanted to mice to develop the second 
generation PDX tumors (F2) with a consistent tissue volume for further experiments. Male 
athymic NCr nude mice between 6 to 8 weeks old were purchased from Taconic (Hudson, 
NY) to develop the orthotopic metastatic tumor models as previously reported (41–45). 
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Briefly, HCT 116 cells expressing green fluorescent protein (GFP) were injected into the 
spleen capsule of mice and allowed to develop liver metastatic CRC tumors for 6 weeks.
PNA synthesis
Figure 2 summarizes PNAs used for this study. These PNAs were synthesized according to 
previously reported methods (26–28, 30, 31, 46). Briefly, scaffolds (PEI or PLL) were 
reacted with NHS-activated PEG first in a mixed reaction solvent (water:DMSO:pyridine = 
2:1:1) at room temperature for 2~3 days. PEG-conjugated scaffolds (PEG-PEI or PEG-PLL) 
were purified by dialysis in water and collected by freeze drying. PEG-PEI and PEG-PLL 
were then reacted with palmitoyl chloride in THF at 40°C for 2 h to produce PEG-PEI-PAL 
and PEG-PLL-PAL. Pyridine was added after 15 minutes to scavenge hydrochloric acid 
byproducts. PEG-PEI-PAL and PEG-PLL-PAL were purified by ether precipitation and 
dialysis in water and collected by freeze drying to obtain final products of PNAs.
Preparation of halochromic and non-halochromic PNAs (hfPNA and n-hfPNA)
PNAs were labeled with a halofluorochromic dye (NB) or non-halofluorochromic dyes 
(Alexa546 or IR820) to produce hfPNA and n-hfPNA, respectively. NB and IR820 were 
conjugated to the primary amines in the core of PNAs by reacting the dyes with PEG-PEI-
PAL or PEG-PLL-PAL in methanol at 40°C overnight in the presence of pyridine 
scavenging hydrochloric acid byproducts as previously reported (47). Alexa546 was 
conjugated to PEG-PLL-PLA through the NHS coupling reaction in DMSO at room 
temperature overnight. PEG-PEI(#) scaffold having no PAL was also used as comparison to 
determine the effect of PNA core environment with charge on halofluorochromism of the 
NB-conjugated particles (27, 28). All dye-labeled PNAs were dialyzed in water, purified by 
size exclusion gel columns, and collected by freeze-drying. In this paper, PNAs are denoted 
as hfPNA#/X, hfPNA/X and n-hfPNA/X, where ‘X’ indicates dyes conjugated to the core of 
particle and ‘#’ means the scaffold is PEG-PEI: hfPNA#/NB, hfPNA/NB, n-hfPNA/
Alexa546, n-hfPNA/IR820. Unreacted primary amines of PNAs were either intact 
(hfPNA#/NB and n-hfPNA/Alexa546) or end-capped by acetylation using acetic anhydride 
(hfPNA/NB and n-hfPNA/IR820).
PNA characterization
The chemical compositions of PNAs were determined by proton NMR spectroscopy (Varian 
400 MHz, d6-DMSO, referenced to TMS). Dye conjugation was confirmed by UV-VIS 
spectroscopy of free dye standards and dye-conjugated PNAs using a plate reader 
(SpectraMax M5, Sunnyvale, CA). The relative size distribution and chemical uniformity of 
PNAs were determined by gel permeation chromatography (GPC, Asahipak GF-7M, PBS, 
0.5 mL/min, 40°C, calibrated using PEG standards). The diameter and surface charge of 
PNAs were determined by dynamic light scattering (DLS, Zetasizer Nano ZS, Malvern, 
UK). In vivo imaging system (IVIS, Xenogen IVIS-200, PerkinElmer, USA) was used to 
visualize fluorescence from PNAs in tissue mimics or animal tissue samples for ex vivo 
studies as further detailed below.
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PNA diffusion and flux measurement in gel tissue mimics
Tissue mimics were prepared by using agarose gels. Agarose (0.5% or 1% w/v) in buffer 
solutions (pH 7.4, 7.0 and 6.0) was completely dissolved by heating, and the agarose 
solution was pipetted into wells of a 96 well plate (100 μL per well). The plate was allowed 
to cool at room temperature to create gels with varying agarose content mimicking normal 
and tumorous tissue conditions. Stock solutions of hfPNA/NB (10 mg/mL) and n-hfPNA/
IR820 (1 mg/mL) were prepared in deionized water, and 100 μL of each PNA solution was 
added to the wells containing agarose tissue mimics. n-hfPNA/IR820 was allowed to diffuse 
into the tissue mimics at 37°C for 0.1, 0.5, 1, 3, 6 or 24 h, and hfPNA/NB was incubated for 
24 h for comparison. The experiments were performed in a chamber with no additional or 16 
kPa (120 mm Hg) external pressure to mimic capillary and interarterial pressure forcing 
PNAs into liver stroma, respectively. After incubation, PNA solutions were removed from 
the plates for spectroscopy measuring signals from particles in the gels. The measured 
values were normalized by subtracting background signals from untreated wells, and data 
was fitted to a linear regression. Absorbance changes of n-hfPNA/IR820 were converted into 
flux by dividing the slopes from the linear regression by the well surface area and 
multiplying the initial PNA concentration in each well. Fluorescence of hfPNA/NB was 
measured by using IVIS (Ex 640 nm/Em 700 nm) to determine halofluorochromic changes 
in tissue mimics with varying acidity.
PNA stability evaluation under opsonization conditions
PNAs were exposed to anionic, cationic, physiological, and serum-containing conditions that 
commonly induce nanoparticle aggregation as reported in literature (48–51). n-hfPNA/
IR820 was dissolved at 2 mg/mL in stock solutions of magnesium sulfate (anionic, 1 M), 
calcium chloride (cationic, 30 mM), McCoy’s 5A media (physiological), and McCoy’s 5A 
containing FBS (serum-containing, 50% v/v) and incubated at 37°C for 0, 1, 3, 6 and 24 h. 
Potential particle aggregation was observed by monitoring absorbance changes at 650 nm. 
Absorbance increases above 0.3 indicating 50% turbidity were defined as significant 
aggregation of PNAs. The diameter of PNAs was also measured after 24 h of incubation and 
compared it to the initial particle size.
PNA cellular uptake measurement
HT29 cells were seeded at 15,000 cells per well in chamber slides. After overnight 
incubation, the media was replaced and cells were treated with hfPNA#/NB (1 mg/mL), 
hfPNA/NB (1 mg/mL), or MG (200 nM) at 37°C for 0.5, 1, 3, and 6 h. The treated cells 
were then placed on a heated stage at 37°C and imaged using a fluorescence microscope 
(Zeiss Axiovert 200M, Thornwood, NY). hfPNA#/NB and hfPNA/NB were imaged using a 
Texas red filter (Ex 568 nm/Broad Spectum Em) and MG was observed using an FITC filter 
(Ex 488 nm/Broad Spectrum Em). Fluorescence of hfPNA#/NB, hfPNA/NB, and MG was 
normalized to the background signals of each timepoint, and the average intracellular and 
extracellular fluorescence at each time point were calculated using ImageJ (NIH, Bethesda, 
MD). A ratio of intracellular to extracellular fluorescence was defined as the uptake quotient 
(Q) in equation 1.
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(1)
PNA cellular uptake equilibrium was also determined by taking cell images every 10 
seconds for 0.5 h immediately after sample treatment to the cells. hfPNA/NB and 
hfPNA#/NB were compared to determine the effect of PNA core environment on 
halofluorochromism involved with particle diffusion. A mathematical model of nanoparticle 
cellular uptake was derived for the comparison as previously reported (52). A full derivation 
of the model is included in the Supplementary Information, and equation 2 describes the 
cellular uptake of PNAs as a function of time.
(2)
KEQ is the cellular partition coefficient and k is the cellular uptake rate constant. The time 
for the uptake coefficient to reach 95 percent of the equilibrium value was also defined as 
t95.
PNA accumulation in PDX tumors
Mice bearing F2 PDX tumors were dosed with n-hfPNA/Alexa546 (10 mg/kg) by tail vein 
injection. Mice were euthanized at 1, 4, 8 and 24 h post injection to collect lung, liver, 
kidney, spleen, and PDX tumor tissue samples. PBS was used as a control. The fluorescence 
of n-hfPNA/Alexa546 in tissue samples was quantified by ex vivo imaging with IVIS. 
Fluorescence density maps were created for PNAs in each tissue sample using Living Image 
(Caliper Life Sciences, Hopkinson, MA), and the maps were represented as a color gradient 
centered at maximal fluorescence intensity.
PDX tumor tissue samples were further analyzed by fluorescence microscopy. Tissue 
samples were fixed in 4% paraformaldehyde solution containing 10% sucrose at 4°C. The 
fixed tissue samples were embedded in OCT on dry ice, sectioned at 10 μm thickness, and 
dried overnight in the dark. The tissue samples were washed with PBS, stained with Hoechst 
33342 (or DAPI), and put in an aqueous permanent mounting medium. PDX tumor tissue 
samples were also treated with EpCAM or CD31 antibodies and NL637-labelled IgG 
secondary antibodies to visualize cancer cells and blood vessels for fluorescence imaging 
with a laser scanning confocal microscope (Olympus FV1000, Tokyo, Japan).
PNA accumulation in liver metastatic tumors
n-hfPNA/Alexa546 was injected at varying doses (0, 5, 10 and 20 mg/kg) into tumor-free 
mice through the tail vein to determine baseline fluorescence signals from lung, liver, kidney 
and spleen tissue samples for IVIS imaging (Ex 535 nm/Em 580 nm). Mice bearing 
orthotopic liver metastatic CRC tumors were then injected with n-hfPNA/Alexa546, 
hfPNA/NB, or PBS intravenously, and liver tissues samples were collected for macroscopic 
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imaging with IVIS. Tissue samples fixed for a confocal microscopic imaging were stained 
with DAPI, EpCAM and CD31 antibodies, and NL637-labelled IgG secondary antibodies.
Fluorescence corresponding to cell nuclei (DAPI), blood vessels (CD31), cancer cells 
(EpCAM), and PNAs was then quantitatively analyzed from microscopic fluorescence 
images of liver metastatic CRC tissue samples. Fluorescence signals from liver metastatic 
CRC images were split into RGB channels. Signals isolated from each channel were 
normalized by converting the fluorescence intensity to binary signals using ImageJ to 
account for the differences in signal strength among dyes, dye-labelled antibodies, and 
PNAs. Regions of interest (80 × 80 μm) corresponding to metastatic tumor foci were 
selected and fluorescence per unit area was quantified in each region. Normalized 
fluorescence values per unit area were used to estimate the density of blood vessels and 
cancer cells in liver metastatic tumors for computational simulations in the next section.
Computational simulation of PNA distribution
Computational modeling to evaluate PNA distribution in metastatic CRC tumors was 
developed in our recent publication (53) and builds upon previous modeling work (54–56). 
In this study, the modeling was applied to describe PNA distribution in metastatic CRC 
tumors as a function of vascularization in the surrounding tissue. Accordingly, three vascular 
densities (termed “low”, “medium”, and “high”) were considered to evaluate PNA 
accumulation based on varying degrees of vascular access to the lesions. The model is 
described in detail in the Supplementary Information.
Statistics
All values are reported as mean ± standard deviation for triplicate measurements. Statistical 
analysis of multiple measurements was performed using the one-way ANOVA with 
Bonferroni’s post test correction. Analysis of pairs of measurements was performed using a 
Student’s t test. All values from mathematical modeling are reported as mean ± standard 
error of the mean. Statistical significance is represented with * (p<0.05), ** (p<0.01), or *** 
(p<0.001).
RESULTS
PNA Synthesis
DLS confirmed that all PNAs were uniform in size with an average diameter between 19 ~ 
34 nm and neutral surface charge: hfPNA#/NB (26.5 ± 8.8 nm, ζ = −0.6 ± 0.4 mV), 
hfPNA/NB (34.3 ± 3.5 nm, ζ = −1.3 ± 0.3 mV), n-hfPNA/Alexa546 (23.2 ± 1.0 nm, ζ = 
−0.8 ± 0.4 mV), and n-hfPNA/IR820 (18.8 ± 0.3 nm, ζ = 0.3 ± 0.7 mV). NMR analysis 
revealed that PEG content on the PEI or PLL scaffold was 10 ~ 24 % with PAL substitution 
of 37 ~ 55% with respect to primary binding sites on the scaffold (Table 1). Characterization 
information of hfPNA#/NB and hfPNA/NB are provided from literature (47). The purity of 
PNAs were confirmed by GPC as shown in Supplementary Information (Figure S1). These 
results are consistent with our previous observations (26–28, 30, 31, 46), and indicate that 
conjugation of fluorescent dyes to the core of PNAs induces minimal changes to the 
uniformity and size of the nanoparticles used in this study.
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PNA diffusion into tissue mimics
Figure 3 shows the flux of n-hfPNA/IR820 into agarose gel tissue mimics with and without 
additional external pressure. The flux of n-hfPNA/IR820 decreased by ~40% in 1% gels 
compared to 0.5% gels. Decreases in gel pH did not affect the flux of n-hfPNA/IR820. 
Additional external pressure increased the flux at 0.1 and 0.5 h post treatment, but it did not 
significantly change the flux at 6 and 24 h post treatment. Calculated flux values for each gel 
density, pH, and pressure are summarized in Table 2. We confirmed that n-hfPNA/IR820 
showed no significant change in fluorescence intensity as a function of solution pH (Figure 
S2). These results suggest that PNAs have limited diffusion into normal and tumor tissues 
and they may distribute mainly in the interstitial space of the liver while circulating through 
blood vessels post intravenous injection.
Halofluorochromic detection of tissue acidity
Figure 4 shows hfPNA/NB detecting pH changes in tissue mimics. hfPNA/NB increased 
fluorescence intensity in agarose gels representing acidosis in normal and tumor tissues 
(Figure 4A). Quantitative analysis shows that hfPNA/NB increased fluorescence in order of 
pH 7.4 < 7 < 6 (Figure 4B). PNAs showed greater fluorescence intensity in 0.5% gel than in 
1% gel because they diffused into 0.5% agarose gel slightly better than 1% agarose gel as 
shown in Figure 3. It is unclear why PNAs showed the greatest fluorescence intensity in 1% 
gel at pH 6, but the spotted distribution of PNAs in the well might have increased the overall 
fluorescence. These results confirm that hfPNAs can detect pH changes in tissue mimics 
despite limited particle diffusion.
PNA stability
Figure 5 shows that PNAs are stable enough to avoid precipitation under opsonization 
conditions for at least 24 h. PNAs incubated in a cationic solution and cell culture media 
showed turbidity at 650 nm absorbance decreasing slightly immediately after incubation yet 
remaining stable from 1 to 24 h (Figure 5A). Although PNAs showed the lowest absorbance 
at 650 nm in an anionic solution, there was no significant difference among PNAs in terms 
of particle size during incubation (Figure 5B). These results demonstrate that PNAs are 
suitable for carrying imaging agents in the body without inducing particle precipitation in 
the physiological condition for a long time.
Cellular uptake
Figure 6 indicates low cellular uptake of PNAs as opposed to small molecule MG. Figure 
6A and 6B display PNAs remaining outside cells for up to 6 h regardless of formulation 
(hfPNA#/NB vs hfPNA/NB). In contrast, MG entered cells quickly and increased its cellular 
uptake over time (Figure 6C). PNAs showed at least 12 times less cellular uptake than MG 
for 6 h of incubation (Figure 6D). Interestingly, cellular uptake of PNAs reached equilibrium 
in about 5 and 10 minutes for hfPNA/NB and hfPNA#/NB, respectively (Figure 6E). Figure 
6A and 6B show truncated dark spots of cells, which suggest that PNAs accumulated neither 
in the cytosol nor cellular membrane at a detectable level. There are two possible 
explanations of these findings. PNAs may be taken up by cells quickly yet they are recycled 
back to the outside of the cell reaching apparent equilibrium at low cellular uptake. Another 
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explanation of the low cellular uptake of PNAs is that the nanoparticles could accumulate 
mainly in the cellular membrane and reach equilibrium. The parameters from the 
mathematical modeling of PNA uptake are in Table 4. Differences in the cellular partition 
coefficient (p<0.001), cellular uptake rate constant (p<0.001), and the time to reach 95% of 
equilibrium (p<0.01) for hfPNA#/NB and hfPNA/NB are statistically significant. These 
results indicate that PNAs are not easily taken up by the cells and remain outside cells 
during incubation, which is favorable for the nanoparticles to detect tissue pH within liver 
metastatic CRC tumors in vivo.
PNA accumulation in PDX Tumors
Figure 7 shows n-hfPNA/Alexa546 accumulating in PDX tumors. PNAs showed 
fluorescence increasing gradually in tumors for 24 h after intravenous injection, but their 
fluorescence remained low in other major organs such as lungs, kidney, spleen, and liver. 
Fluorescence from PNAs in lungs was its maxima at 1 h post injection and decreased over 
time. These results indicate that PNAs accumulate preferentially in tumors and avoid non-
specific accumulation in other major organs. Low PNA accumulation in major organs is 
consistent with low cellular uptake of PNAs confirmed by in vitro studies (Figure 6). 
Enhanced PNA accumulation in tumors suggests that tissue microenvironment may differ 
between tumor and other major organs. Nanoparticles are known to stay longer in tumor 
tissue, a phenomenon generally known as the enhanced permeation and retention (EPR) 
effect (13, 57). According to the EPR effect, macromolecules penetrating disrupted blood 
vessels found in tumor or inflammation lesions can remain for an extended time if the 
lymphatic drainage is compromised (57). Another explanation is that tumor macrophages 
might have taken up PNAs and thus increased nanoparticle accumulation in tumors for 
enhanced fluorescence. However, as seen in Figure 5 and 6, PNAs show no opsonization and 
low cellular uptake and they may not interact with tumor macrophages easily. Although 
further studies are necessary to elucidate the detailed mechanism, PNAs are confirmed to 
accumulate in PDX tumors that retain a complicated tissue environment seen in patient 
tumors, and the nanoparticles are likely trapped in the interstitial space of PDX tumors. To 
test this hypothesis, we further investigated PNA distribution in PDX tumor tissue by 
fluorescence microscopy.
PNA distribution in PDX tumor tissue
Figure 8 shows distribution of n-hfPNA/Alexa546 in sliced tissue samples from PDX tumors 
shown in Figure 7. The images clearly display PNAs accumulating between tumor cells and 
increasing its fluorescence over time (Figure 8A). It must be noted that the fluorescence of 
PNAs remains near cell nuclei in all images, suggesting that the nanoparticles may be in the 
cytosol of tumor cells. These results are different from in vitro observations showing low 
cellular uptake of PNAs. PNAs may interact differently with various cell types other than 
tumor cells, which include endothelial cells forming tumor blood vessels. In Figure 8B, 
PNAs (red) seem to co-localize with cancer cells stained with EpCAM (green), although the 
signal is weak. Figure 8C shows that CD31-stained endothelial cells (green) do not always 
co-localize with PNAs (red), supporting low cellular uptake of PNAs. These results 
demonstrate that PNAs accumulate in or near endothelial cells forming tumor blood vessels 
and minimally enter endothelial or PDX tumor cells for 24 h post injection.
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PNA accumulation in orthotopic liver metastatic CRC tumors
Figure 9 compares distributions of n-hfPNA/Alexa546 and hfPNA/NB in liver with 
orthotopic metastatic CRC tumors. Although n-hfPNA/Alexa546 accumulating tumors in the 
liver increased fluorescence, the nanoparticle also shows strong fluorescence in liver, kidney, 
and lung tissues, and the high background signal makes it difficult to distinguish tumors 
from normal liver tissue (Figure 9A). In contrast, hfPNA/NB shows fluorescence selectively 
in tumors presumably because the nanoparticle is able to detect acidic tumor tissue in the 
liver (Figure 9B). Despite the encouraging results, the distribution pattern of hfPNA/NB 
(red) does not match to the areas where tumor cells (green) are in Figure 9B. These results 
indicate that hfPNA/NB can successfully detect acidic tissue of metastatic tumors but it may 
fail to pinpoint every metastatic tumor foci with no acidosis in macroscopic images.
Microscopic analysis of PNA distribution in orthotopic liver metastatic CRC tumors
Figure 10 shows distribution of n-hfPNA/Alexa456 in metastatic CRC tumors in the liver. 
PNAs (red) are near endothelial cells in the stromal tissue of liver (green) and they show low 
cellular uptake. PNAs distribute mainly in the interstitial space of metastatic tumors, 
showing a clear contrast to the nanoparticle distribution pattern in PDX tumors (Figure 8). 
The difference in PNA distribution between PDX and orthotopic liver metastatic CRC 
tumors suggest that halofluorochromism may be more useful to detect metastatic tumors 
than primary solid tumors by microscopic image analysis. PNAs accumulating in the 
interstitium of metastatic tumors clearly separate tumor foci from normal tissues by 
visualizing the ‘silhouette’ of tumors.
Meanwhile, orthotopic liver metastatic tumors were confirmed to have less blood vessel 
density than the normal liver tissue, and PNAs seemed to show brighter fluorescence in the 
liver than metastatic tumors (Figure 10 and S4). DAPI staining of tissues indicates that 
nuclei (blue) are larger and less dense in healthy liver tissue compared to metastatic tumors. 
CD31 staining indicates that liver tissue contains more blood vessels than metastatic CRC 
tumors. The reduced density of blood vessels suggests that metastatic tumors are less 
perfused with blood than healthy liver tissue. Fluorescence signals corresponding to n-
hfPNA/Alexa546 are weak throughout liver tissue because PNAs perfuse liver tissue. Weak 
fluorescence of n-hfPNA/Alexa546 is also observed in space surrounding dense colonies of 
cancer cells in metastatic tumors, and fluorescence decreases further near the interior of 
these colonies. These results suggest that PNAs diffusing away from blood vessels fail to 
perfuse metastatic tumors. Alternatively, PNAs could have washed away from the tissue 
during the sample preparation procedure involved with formaldehyde fixation, dye staining, 
fluorescent antibody immunostaining, and PBS washing. Therefore, hfPNAs could emit 
much stronger fluorescence in in situ intraoperative imaging of tumors in the clinic. It must 
be noted that small spots of PNA fluorescence were seen in the zoomed images of liver 
tissue and metastatic tumors. These spots may be attributed to accumulation of PNAs in 
lysosomes or vesicles inside the cells near blood vessels although the exact cause is unclear.
Computational simulation of PNA distribution in metastatic tumors
Figure 11 shows qualitative results displaying the accumulation of PNAs in simulated 
metastatic CRC tumors at 1.8 h and 12 h after intravenous injection. The PNA accumulation 
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was computationally evaluated for low, medium, and high levels of surrounding tissue 
vascularization based on values experimentally determined in vivo. Regardless of tumor 
vascularization, most PNAs remain in the extracellular matrix surrounding the lesion and 
adjacent tumor tissue, and PNAs increased accumulation in the periphery of the simulated 
metastatic lesions as the vascular density increased (Figure 11A). Figure 11B shows that 
PNAs accumulating near a metastatic lesion decrease to about half of their initial amount at 
12 h post injection.
Figure 12 summarizes the simulated PNA accumulation in various tissue regions of liver 
metastatic tumors for up to 2.5 days after intravenous injection. The total PNA concentration 
based on vasculature area (μm2, based on vessel length × circumference) has the largest peak 
in the medium vascularization case (0.20), and the peak concentration in the hypoxic tissue 
is reached in the high vascularization case (0.057). One day after intravenous injection, the 
total PNA concentration decreased by 75%, 80%, and 90% for the low, medium and high 
vascularization cases, respectively. These results reflect increased PNA washout with a 
higher number of blood vessels present.
Figure 13 quantifies the PNA accumulation per vasculature area at 1.8 h and 12 h post 
injection depending on vascularization and tumor region (proliferating, hypoxic, necrotic, 
and blood vessels). The PNA concentration in the proliferating regions at 1.8 h was 10, 7.8, 
and 7.5 times higher than in the hypoxic regions for the low, medium, and high 
vascularization conditions, respectively. PNA concentrations became more comparable by 
12 h (1,8x, 2x, and 1.2x, respectively) with the nanoparticle accumulation decreasing by 
~75% in the proliferating regions and by ~50% in the tumor blood vessels. PNAs 
accumulating in the hypoxic tissue increased by ~100% regardless of vascular density. In all 
cases, PNA accumulation in the necrotic regions was negligible.
The results of the computational modeling suggest that although a higher number of PNAs 
may be initially taken up by the proliferating regions, PNA accumulation in the hypoxic (and 
more acidic) tissue of the lesion would increase and remain steady for at least several hours 
after systemic injection. Most importantly, this accumulation pattern seems independent of 
the vascularization degree of the tissue surrounding the lesions.
DISCUSSION
Early and accurate detection of metastatic CRC tumors in the liver may significantly 
improve CRC treatment and reduce mortality in cancer patients, but traditional diagnostic 
methods have several limitations to identify small metastatic tumors that rarely affect the 
structure or morphology of surrounding tissues (58). For example, MRI, PET, CT, and other 
imaging systems for cancer diagnosis are ineffective to detect small metastatic tumors 
because contrast agents used for these diagnostic techniques fail to diffuse into such tumors 
and stay within them for a sufficient time (59). Fluorescent dyes are also widely used to 
visualize cancer cells and identify small tumors during intraoperative imaging, but common 
issues include poor diagnostic properties such as low signal-to-noise ratios and short half-
lives in vivo (60). In order to overcome these limitations, nanoparticles entrapping small 
molecule imaging dyes have been recently developed.
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Nanoparticles entrapping imaging dyes increased the intensity and durations of dye signals 
from solid tumors, which allowed for the fluorescence imaging-guided detection of tumors 
(61). In addition, nanoparticles entrapping fluorescent dyes may allow for the selection of 
metastatic tumors during surgery for further immunohistochemical analysis. Previous studies 
confirmed that nanoparticles accumulate in solid tumors through the EPR effect and extend 
blood retention time of small molecule drugs and dyes. Nanoparticles delivering therapeutic 
and diagnostic agents simultaneously to tumors can combine cancer therapy and diagnosis, 
which may be also beneficial to treat metastatic tumors. These ‘theranostic’ nanoparticles 
are often labeled with fluorescent dyes to trace their distribution in the body. However, 
fluorescent nanoparticles can increase background signals in normal tissues, particularly the 
liver, lungs, spleen, and kidneys, and hinder the detection of metastatic tumors (62, 63). To 
suppress background fluorescence and detect metastatic CRC tumors more accurately at an 
earlier stage of development, we developed PNAs entrapping halofluorochromic dyes (26–
28).
Halofluorochromism is a unique optical property for dyes to change their fluorescence 
wavelength and intensity as a function of environmental pH. In this study, we focused on 
determining whether hfPNAs could differentiate tissue pH and detect liver metastatic CRC 
tumors with acidic tissue (Figure 1). We first prepared hfPNA and n-hfPNA formulations 
with uniform size to monitor distribution of PNAs using dyes that change or retain 
fluorescence signals as a function of tissue pH (Table 1 and Figure 2, S1, and S2). These 
PNAs appeared to poorly diffuse into normal and tumor tissues (Figure 3 and Table 2), 
although they can detect tissue pH regardless of tissue density (Figure 4). Limited tissue 
diffusion of PNAs is probably attributed to colloidal stability in maintaining ‘stealth’ 
properties for the PEG coating to prevent particle aggregation and opsonization (Figure 5). 
Stable PNAs showed low cellular uptake with minimal interaction with the cell membrane of 
cancer cells (Figure 6), which reached equilibrium in 10 minutes after incubation (Table 3 
and 4). PNAs with poor tissue diffusion and low cellular uptake accumulated and stayed in 
PDX tumors for at least 24 h (Figure 7 and 8), which is beneficial to image tumors for a long 
time. It must be noted that PNAs showed these properties regardless of halofluorochromism. 
Interestingly, however, n-hfPNAs failed to detect small liver metastatic tumors as their 
background fluorescence signals spread over normal tissues of major organs (Figure 9).
n-hfPNAs slightly increased fluorescence in a brightfield image of liver metastatic tumor 
lesions (Figure 9A), but they failed to provide an image resolution to differentiate tumors 
from liver stroma (Figure S3). In contrast, hfPNAs emitted fluorescence from tumor tissues 
with high accuracy, presumably by detecting acidic interstitial tissue between metastatic 
tumors and liver stroma (Figure 9B and Figure 10). This speculation is supported by the 
observation that the fluorescence signals from hfPNAs did not perfectly correspond to liver 
metastatic CRC tumors (green vs red signals in Figure 9B). Our observations suggest that 
hfPNAs may emit fluorescence only in some sections of acidic tumor tissue as they 
distribute differently in metastatic CRC tumors compared to the liver (64). It should be noted 
that halofluorochromism relies on the detection of an acidic tumor microenvironment, and 
that halofluorochromism may not detect very small metastatic tumor foci with no acidosis. 
In future clinical applications, the halofluorochromic PNAs should be used in combination 
with other diagnostic tools due to these limitations. To elucidate how hfPNAs detect small 
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metastatic tumors, we further investigated microscopic distribution of PNAs in metastatic 
tumors with assistance of computational modeling.
We previously reported that PNAs could maximize accumulation of therapeutic agents in 
solid and metastatic tumors by fine-tuning their drug release (35). In this study, we expanded 
our computational approach to predict distribution of PNAs in metastatic tumors with 
varying surrounding tissue blood vessel densities (Figure 11) based on a range of 
experimentally observed values (Figure 8, 10, and S4). The simulations evaluated the effects 
of physical and biological factors such as tissue diffusion, cell interactions, and opsonization 
on metastatic CRC tumor detection in the liver up to 2.5 days post injection (Figure 12). The 
data shows that PNAs reach similar accumulation levels in the acidic interstitium of 
metastatic tumors within 12 h post injection irrespective of vascularization (hypoxic area 
data in Figure 12), while medium vascularization induced maximum PNA accumulation in 
metastatic tumor tissues (Figure 12B). It is noticeable that PNA accumulation in acidic 
tumor tissue is projected to increase over time while particle concentrations in other tissue 
areas are expected to decrease (Figure 13). These findings support the notion that hfPNAs 
hold promise to detect small liver metastatic CRC tumors and thus may be useful to develop 
novel theranostic tools.
Despite these exciting results, several questions remain to be addressed in future studies. 
Although PNAs accumulated in liver tissue with metastatic CRC tumors, the diffusion rate 
of PNAs into tissue was difficult to determine accurately due to fluctuations in tissue 
density, interstitial space volume, and tissue pH. To accurately measure tissue diffusion rates 
for PNAs, we used agarose gel tissue mimics with controllable mass transport properties 
such as density and pH. Low gel density (0.5% w/v) creates pores mimicking the 
extracellular space between healthy cells (200 to 500 nm), while high gel density (1.0% w/v) 
provides pores corresponding to the keratin mesh surrounding tumors (50 to 100 nm) (65). 
The acidity of the gels represents either healthy tissue (pH 7.4), tumor periphery (pH 7) or 
the tumor core (pH 6) (66). Mass transport in agarose gels has been well studied for physical 
separation methods such as electrophoresis and gel blotting. Unlike ionizable molecules that 
change their diffusion rates into agarose gels as a function of pH, PNAs lacking surface 
charge had consistent flux into agarose gels between pH 7.4 and 6 (Figure 3 and Table 2). 
There were small pH-dependent variations in flux, but these variations did not represent an 
overall trend. High gel density reduced PNA flux by ~40% compared to a low gel density. 
Pores in both gels are large enough (50 to 500 nm) for 30 nm PNAs to enter. If real tumors 
have smaller pores, it may increase interactions between pores and PNAs slowing long-
range diffusion.
We also acknowledge that gel mimics have several physical and chemical limitations in 
accurately reproducing tissue conditions that could reduce the accuracy of gels to estimate in 
vivo PNA diffusion rates. For example, gel mimics lack biological components such as 
lipids and proteins that can affect pore structure and PNA interactions during diffusion (66). 
In addition, tumors have high interstitial tissue pressure due to disrupted lymphatic drainage, 
which can further influence PNA transport into metastatic CRC tumors (67). Previous 
studies show that high intratumoral pressure limits the diffusion of small molecules and 
nanoparticles into solid tumors (68, 69). In this study, we performed gel diffusion 
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experiments in a high pressure chamber to simulate various tissue conditions. Additional 
external pressure mimicking blood pressure (120 mmHg) increased initial the entry of PNAs 
into tissue mimics (<0.5 h) but failed to further enhance PNA diffusion (> 0.5 h). These 
results conclude that external pressure may force small amounts of PNAs into tumor tissue 
initially, but blood pressure cannot force PNAs into tumors with high intratumoral pressure. 
PNAs may change tissue diffusion patterns in patient tumors altering tissue pressure and 
other microenvironmental factors in various disease states.
Opsonization and aggregation of PNAs with cancer targeting molecules on the surface can 
reduce tumor accumulation, decrease blood half-life, and increase interactions between 
PNAs and immune cells (70, 71). PNAs showed negligible opsonization or aggregation in 
vitro (Figures 5A and 5B). PEG shell seems to shield fluorescent dyes from molecules in 
solution and allow the dyes to detect the tumor microenvironment. However, fluorescence 
imaging of hfPNAs shows that the PEG shell does not prevent the diffusion of small acidic 
molecules into the PNA core, which allows for detection of the acidic tissue (Figures 4A and 
4B). Taken together, these results suggest that PNAs with minimal opsonization allow 
fluorescent dyes to remain in blood and detect acidic tumors or tumor metastasis.
The accumulation of hfPNAs in the cytosol or endosomes of cancer cells may prevent 
detection of the acidic extracellular tumor microenvironment. Intracellular uptake of PNAs 
reached equilibrium at 0.5 h post treatment, but small molecule dye MG accumulated in 
cells up to 6 hours post treatment (Figure 6D). All PNAs showed low cellular uptake (Table 
3) with < 0.01% of total PNAs found inside cells in chamber slides, which was estimated 
from intracellular volume, extracellular volume and measured equilibrium cellular partition 
coefficients (Table 4). Surprisingly, hydrophobic core modifications slightly increased the 
uptake of PNAs despite shielding of the hydrophobic core by the PEG shell, suggesting that 
core of PNAs may interact weakly with the cell membrane through hydrophobic 
interactions. Ex vivo tissue imaging also verified low cellular uptake of PNAs in liver 
metastatic CRC tumors (Figure 10). In metastatic CRC tumors, most PNAs were found near 
blood vessels (CD31-positive endothelial cells). However, PNAs were found throughout 
healthy liver tissue with high vasculature. These results suggest that hfPNAs remain in the 
extracellular space of liver stroma and detect the acidic extracellular microenvironment 
indicating metastatic CRC tumors, but tumor macrophages and other phagocytes in tumor 
tissue may be involved.
Results from this study suggest that PNAs diffuse throughout healthy and tumor tissue 
(Figure 3) yet remain in the extracellular space surrounding tumor cells (Figure 6). 
Macroscopic imaging of n-hfPNAs in liver tissue (Figure 9) implies that PNAs accumulate 
throughout the liver and metastatic lesions. Because of high background signals in healthy 
liver tissue and minimal accumulation in metastatic tumors, n-hfPNAs failed to identify 
metastatic tumors. Microscopic imaging of n-hfPNAs showed only small amounts of PNAs 
accumulating in the interstitium of metastatic tumors (Figure 10), probably because PNAs 
outside of cells were washed away during sample preparation for microscopy. In contrast, 
hfPNAs fluoresced strongly in acidic microenvironments (Figure 4) and identified metastatic 
tumors in the liver (Figure 9B). Computational simulations verified that accumulation of 
PNAs in hypoxic acidic regions of MCRC tumors following systemic administration 
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(Figures 11, 12 and 13), although this accumulation was small compared to overall PNA 
signals from the liver. Therefore, hfPNAs may suppress background signals in healthy 
tissues surrounding metastatic tumors and accumulate in hypoxic regions to detect small 
metastatic tumors.
Computational modeling of hfPNAs accumulation in patient tissues from biopsy samples 
may facilitate clinicians to identify tumors and determine effective treatment regimens. The 
simulation results indicate that PNAs readily accumulate near the perimeter and within 
tumor metastases (Figure 11). This prediction agrees with the observed accumulation of 
PNAs in microscopic fluorescence imaging (Figure 10). The accumulation of PNAs is 
projected to remain steady within hypoxic (more acidic) tumor regions (Figures 12 and 13). 
The accumulation of PNAs in hypoxic regions of PNAs allows for the halofluorochromic 
detection of liver metastatic CRC tumors (Figure 4). This is consistent with our experimental 
results showing that PNAs near the perimeter of tumors can increase fluorescence and help 
identify the acidic environment of metastatic tumors. Future experimental work combined 
with computational modeling will need to determine the minimum size of metastatic CRC 
tumor foci that hfPNAs can detect.
CONCLUSIONS
In this study, we have confirmed that hfPNAs may be a promising tool for detection of liver 
metastatic CRC tumors. Data shows that PNAs would diffuse throughout healthy and tumor 
tissue, yet remain outside cancer cells. Macroscopic imaging implies that PNAs accumulate 
throughout the liver and emit halofluorochromic signal in the interstitial space between liver 
and tumor tissues. However, microscopic imaging showed only small amounts of PNAs 
accumulating in the interstitial space, probably because PNAs outside cells were washed 
away during sample preparation for microscopy. Nevertheless, hfPNAs fluoresce strongly in 
acidic microenvironments and identify metastatic CRC tumors as opposed to n-hfPNAs 
accumulating throughout liver tissue to falsely identify metastatic CRC tumors. 
Computational simulations evaluated hfPNAs accumulation in hypoxic, acidic regions of 
metastatic CRC tumors following systemic administration. The combined experimental and 
computational results suggest that hfPNAs may effectively detect liver metastatic CRC 
tumors.
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ABBREVIATIONS
PNA Polymer nanoassembly
CRC Colorectal cancer
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PEG Poly(ethylene glycol)
PEI Poly(ethylene imine)
PLL Poly(lysine)
PAL Palmitatic acid
NB Nile blue
hfPNA Halofluorochromic PNA
n-hfPNA Non-halofluorochromic PNA
hfPNA#/NB hfPNA with PEG-PEI scaffold labeled with NB dye
hfPNA/NB hfPNA labeled with NB dye
n-hfPNA/Alexa546 n-hfPNA labeled with Alexa546 dye
n-hfPNA/IR820 n-hfPNA labeled with IR820 dye
PDX Patient-derived xenograft
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Figure 1. 
Conceptual description of approaches to detect liver metastatic CRC tumors by using 
halofluorochromic PNAs and computational simulations.
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Figure 2. 
Synthesis scheme for halofluorochromic and non-halofluorochromic PNAs (hfPNAs and n-
hfPNAs).
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Figure 3. 
Diffusion of n-hfPNA/IR820 into 0.5% and 1% gels with and without effects of arterial 
pressure at pH 7.4, 7.0 and 6.0.
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Figure 4. 
Halofluorochromism of hfPNA/NB diffused into gels for 24 hours (A). Fluorescence 
increases significantly below pH 7.4 for gels at high and low density (B).
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Figure 5. 
Aggregation of PNAs measured by absorbance changes (A). Particle size changes of PNAs 
after 24 h under aggregating conditions (B).
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Figure 6. 
Cellular uptake imaging of hfPNA#/NB (A), hfPNA/NB (B) and MG (C). Uptake of PNAs 
and MG were compared up to 6 h (D). Uptake of hfPNA#/NB and hfPNA/NB was compared 
for 0.5 h (E).
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Figure 7. 
Fluorescence imaging of PDX tumors, liver, spleen, kidney and lung from mice that 
intravenously received n-hfPNA/Alexa546.
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Figure 8. 
Microscopic fluorescence imaging of PDX tumors from mice. Blue represents cell nuclei 
(DAPI) and red represents n-hfPNA/Alexa546 (A). Tissue samples were also treated with 
either EpCAM (B) or CD31 antibodies (C), and green represents cancer and endothelial 
cells in respective images. (Bar = 100 μm)
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Figure 9. 
Fluorescence images of liver, kidney and lung tissue from mice bearing orthotopic liver 
metastatic CRC tumors treated with n-hfPNA/Alexa546 (A). Fluorescence imaging of liver 
from healthy mice or mice bearing orthotopic liver metastatic CRC tumors treated with 
hfPNA/NB (B).
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Figure 10. 
Microscopic fluorescence imaging of liver tissue and liver metastatic tumors treated with n-
hfPNA/Alexa546. Blue, green, and red correspond to nucleus, CD31, and PNAs, 
respectively. (Bar = 100 μm)
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Figure 11. 
Computational simulations of PNA distribution in metastatic tumors at 1.8 h (A) and 12 h 
(B) after systemic injection of the nanoparticles for three varying degrees of vascularization 
(low, medium, high) in the surroundings of the tumor. Viable tumor tissue (red) is shown 
enclosing hypoxic (blue) and necrotic (brown) regions. Capillary network is represented by 
rectangular grid, with irregular sprouts simulating blood vessel growth via angiogenesis, 
driven by release of tumor angiogenic factors from the hypoxic tissue within the tumor. PNA 
concentration is normalized to the maximum value in the vessels. (Bar = 250 μm)
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Figure 12. 
PNA accumulation per vasculature area (μm2, based on vessel length and circumference) for 
various tumor regions (proliferating, hypoxic, necrotic, and blood vessels) simulated for 2.5 
days after systemic injection of the nanoparticles. Panels show cases of low (A), medium 
(B), and high (C) vascularization in the surrounding tissue.
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Figure 13. 
PNA accumulation per vasculature area (μm2) obtained via computational simulation at 1.8 
h (A) and 12 h (B) after treatment as functions of tumor region (proliferating, hypoxic, 
necrotic, blood vessels) and tumor vascularization degree in the surrounding tissue.
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Table 2
Calculated flux values for PNAs with 120 mm Hg external pressure.
Flux (kg/(s*cm2))*1010
Pressure (mm Hg) Gel % pH 7.4 pH 7.0 pH 6.0
0
0.5 9.62±0.63 10.08±0.51 10.55±0.71
1.0 7.12±0.39 5.97±0.41 7.12±0.39
120
0.5 8.23±0.55 9.31±0.44 7.73±0.75
1.0 4.35±0.42 7.18±0.43 4.66±0.40
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Table 3
Uptake quotients of cells treated with hfPNA#/NB, hfPNA/NB and MG.
Time (h)
Treatment 0.5 1 3 6
hfPNA#/NB 0.37±0.11 0.22±0.12 0.26±0.10 0.27±0.08
hfPNA/NB 0.33±0.10 0.39±0.11 0.38±0.11 0.40±0.07
Mitotracker Green 0.11±0.12 1.33±0.14 2.37±0.31 12.26±1.92
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Table 4
Parameters for first order association model of PNA uptake.
PNA KEQ (unitless) k (min−1) t95 (min)
hfPNA#/NB 0.25±0.01 0.23±0.01 13.2±0.8
hfPNA/NB 0.41±0.01 0.46±0.01 6.6±0.1
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